The first page of her article and my recent post agree fully. Hard to see where you think one contradicts the other. There are no oppositional views between my post and the front page of her publication. Of course there won't be one treatment for all types. There may actually be multiple disease entities presently grouped under the umbrella of ALS. That's the problem for CUR. The factors that separate their responders from others may as yet be unidentified. Unique biomarkers are largely unknown in the neurodegerative disease family, but they are there, waiting for the technology to discover them to be refined.
FALS and sporadic ALS were approved eligible population of CUR's ph2a study - FYI. There is no reference in her first published page to ineligible participants having participated in the CUR trial.
Part of her article refers to drug trials, and she is putting forth a sound argument for a change in trial structure for this disease group, one that no longer looks towards a primary single endpoint. This is true and needed and will move the disease identification challenges forward.
News 
Market Data 
Discover 
AI
